Therapeutic effect of telbivudine combined with Fuzheng Huayu tablets in treatment of liver fibrosis in chronic hepatitis B: a report of 60 cases

Therapeutic effect of telbivudine combined with Fuzheng Huayu tablets in treatment of liver fibrosis in chronic hepatitis B: a report of 60 cases

ObjectiveTo investigate the therapeutic effect of telbivudine combined with Fuzheng Huayu tablets in the treatment of liver fibrosis in chronic hepatitis B (CHB). MethodsA total of 120 patients with CHB, who were admitted to our hospital from July 2011 to November 2012, were randomly divided into tr...

Full description

Bibliographic Details
Main Author:	DONG Xiaoping
Format:	Article
Language:	zho
Published:	Editorial Department of Journal of Clinical Hepatology 2013-09-01
Series:	Linchuang Gandanbing Zazhi
Subjects:	telbivudine FUZHENG HUAYU TABLET hepatitis B chronic liver cirrhosis
Online Access:	http://www.lcgdbzz.org/qk_content.asp?id=5504&ClassID=869567

Similar Items

Safety and therapeutic effects of anti-fibrotic Traditional Chinese Medicine Fuzheng Huayu on persistent advanced stage fibrosis following 2 years entecavir treatment: Study protocol for a single arm clinical objective performance criteria trial
by: Yangyi Chen, et al.
Published: (2020-09-01)

Fuzheng Huayu recipe prevents nutritional fibrosing steatohepatitis in mice
by: Jia Yan-Hong, et al.
Published: (2012-03-01)

The effect and mechanisms of Fuzheng Huayu formula against chronic liver diseases
by: Jiamei Chen, et al.
Published: (2019-06-01)

Transcriptional Profiling and miRNA-Target Network Analysis Identify Potential Biomarkers for Efficacy Evaluation of Fuzheng-Huayu Formula-Treated Hepatitis B Caused Liver Cirrhosis
by: Qilong Chen, et al.
Published: (2016-06-01)

The Active Components of Fuzheng Huayu Formula and Their Potential Mechanism of Action in Inhibiting the Hepatic Stellate Cells Viability – A Network Pharmacology and Transcriptomics Approach
by: Xinrui Xing, et al.
Published: (2018-05-01)

Active Compounds Derived from Fuzheng Huayu Formula Protect Hepatic Parenchymal Cells from Apoptosis Based on Network Pharmacology and Transcriptomic Analysis
by: Rong Wu, et al.
Published: (2019-01-01)

Effects of Fuzheng Huayu Capsules combined with nucleoside antiviral drugs on liver and kidney function, serum inflammatory factors, TLR-4, TGF-β1 and aspartate aminotransferase-platelet ratio index in patients with HBV infection and decompensated liver
by: Hai-Ling Zhang
Published: (2020-02-01)

In Vitro Antibacterial Experiment of Fuzheng Jiedu Huayu Decoction Against Multidrug-Resistant Pseudomonas aeruginosa
by: Hongri Xu, et al.
Published: (2020-02-01)

Modulation of IKKβ/NF-κB and TGF-β1/Smad via Fuzheng Huayu recipe involves in prevention of nutritional steatohepatitis and fibrosis in mice
by: Rong-Qi Wang, et al.
Published: (2015-04-01)

The Novel Chinese Medicine JY5 Formula Alleviates Hepatic Fibrosis by Inhibiting the Notch Signaling Pathway
by: Yadong Fu, et al.
Published: (2021-09-01)

Meta-analysis on Treatment of Chronic Hepatitis B with Telbivudine and Entecavir
by: Ye Zhen, et al.
Published: (2012-12-01)

Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B
by: Eun Hye Kim, et al.
Published: (2013-03-01)

Progress of Research on Organic Fibrosis with Traditional Chinese Medicine
by: Qing-Lan Wang, et al.
Published: (2016-08-01)

Neutropenia caused by telbivudine in chronic hepatitis B patients: a report of one case
by: WANG Rongqi
Published: (2015-02-01)

THE FIRST EXPERIENCE OF TELBIVUDINE THERAPY IN LIVER TRANSPLANT PATIENTS
by: O. A. Gerasimova, et al.
Published: (2010-06-01)

Comparison of Renal Safety of Tenofovir and Telbivudine in Chronic Hepatitis B Patients: A Real World Study in Indonesia
by: Rino Alvani Gani
Published: (2018-09-01)

Clinical trial of telbivudine in the treatment of chronic hepatitis B in patients during the third trimester of pregnancy
by: JIANG Xiunong
Published: (2013-02-01)

Evaluation of telbivudine’s efficacy for treating HBeAg-positive chronic B hepatitis patients and identification of its predictive factors by logistic regression analysis
by: GUO Ruyi
Published: (2013-02-01)

Growth and development of children prenatally exposed to telbivudine administered for the treatment of chronic hepatitis B in their mothers
by: Huihui Zeng, et al.
Published: (2015-04-01)

Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation
by: Li-fen Han, et al.
Published: (2019-07-01)

The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis
by: Deng Min, et al.
Published: (2012-09-01)

Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections
by: Weiqiang Gan, et al.
Published: (2020-12-01)

Role of tenofovir and telbivudine in treatment of hepatitis B related acute on chronic liver failure
by: Debraj Malakar, et al.
Published: (2021-01-01)

Clinical efficacy of telbivudine and interferon in treatment of HBeAg-positive chronic hepatitis B: a comparative study
by: LI Huoyan
Published: (2015-04-01)

Effects of Shenqi Fuzheng injection on oxidative stress after hepatic ischemia-reperfusion injury
by: Li-Yuan Zhang, et al.
Published: (2021-03-01)

Rhabdomyolysis, lactic acidosis, and multiple organ failure during telbivudine treatment for hepatitis B: a case report and review of the literature
by: Jinxin Zheng, et al.
Published: (2017-11-01)

Efficacy and safety of telbivudine in preventing mother-to-infant transmission of HBV in pregnant women with high HBV DNA load
by: SUN Weihui
Published: (2013-08-01)

Clinical effect and short-term safety of telbivudine in blocking mother-to-child transmission of HBV
by: PAN Yuchen, et al.
Published: (2017-09-01)

Developmental consequences of children born from mothers with telbivudine treatment during late pregnancy: A prospective study with 3-year follow-up
by: Wei Yi, et al.
Published: (2021-01-01)

Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission
by: Weihui Sun, et al.
Published: (2017-04-01)

Observational study on the response of tenofovir monotherapy versus tenofovir plus telbivudine dual therapy in patients with hepatitis B virus related acute on chronic liver failure
by: Abul H Manik, et al.
Published: (2021-01-01)

Effects of Fuzheng Huayu recipe on entecavir pharmacokinetics in normal and dimethylnitrosamine-induced hepatic fibrosis rats
by: Tao Yang, et al.
Published: (2020-01-01)

Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B
by: Yue Ying, et al.
Published: (2018-04-01)

Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy
by: Teerha Piratvisuth, et al.
Published: (2016-04-01)

Progress of Shenqi Fuzheng Injection as Adjuvant Therapy for Malignant Tumors
by: Jing WANG
Published: (2017-09-01)

Subchronic toxicity of herbal compound “Jiedu Huayu” granules in rats
by: Minggang Wang, et al.
Published: (2017-09-01)

Anti-tumor effect of Huayu Jiedu formula on SGC-7901 cancer cell
by: Wei Zheng, et al.
Published: (2016-02-01)

Systematic review and meta-analysis of shenqi fuzheng and chemotherapy combination in the treatment of breast cancer
by: Ying Li, et al.
Published: (2016-10-01)

Clinical study on Qingre Huayu Recipe for non-proliferative diabetic retinopathy
by: Chun-Min Li
Published: (2019-01-01)

Clinical effect of Fuzheng Huayu tablets combined with entecavir in the treatment of chronic hepatitis B liver fibrosis
by: GU Hongtu
Published: (2021-02-01)